This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Yale Cancer Center at 2015 ASCO Annual Conference

May 19th, 2015

Highlights include: new immunotherapy response/survival data for immunotherapy for bladder and lung cancers; advances in small cell lung cancer; exercise and quality of life for cancer survivors; expanding indications for checkpoint blockade

Clinical Science Symposiums:

Saturday, May 30; 9:03 AM - 9:15 AMLocation: E Hall D1Immunotherapy for Every Patient: Check Your EnthusiasmRoy S. Herbst, MD, PhD

Monday, June 1; 3:48 PM - 4:00 PMLocation: E Arie Crown TheaterChimeric Antigen Receptor T-Cell Therapy for B-Cell MalignanciesMadhav V. Dhodapkar, MBBS

Oral Abstract Sessions:

Saturday, May 30; 4:36 PM - 4:48 PMLocation: E Hall D1Small Cell Lung Cancer: A Glimpse of LightRoy S. Herbst, MD, PhD

Monday, June 1; 9:48 AM - 10:00 AMLocation: S102Randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer: The Women's Activity and Lifestyle Study in Connecticut (WALC).Yang Zhou, MD, MPH

Monday, June 1; 10:24 AM - 10:36 AMLocation: S102Impact of the LIVESTRONG at the YMCA Program on physical activity, fitness, and quality of life in cancer survivors.Melinda L. Irwin, PhD, MPH

Monday, June 1; 12:09 PM - 12:21 PMLocation: E450The Potential Role of Allogeneic Stem Cell Transplantation in Peripheral T-Cell LymphomaFrancine M. Foss, MD

Monday, June 1; 9:57 AM - 10:09 AMLocation: E Arie Crown TheaterA phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).Daniel P. Petrylak, MD

Monday, June 1; 3:15 PM - 3:27 PMLocation: S100bcHPV and Epstein-Barr Virus-Related Head and Neck Cancer: Deintensification and SurveillanceBarbara Burtness, MD

Poster Discussion Session:Saturday, May 30; 3:00 PM - 3:12 PM/ Discussing Abstracts: 3009, 3010, 3011, 3012Location: S406Expanding Indications of Checkpoint BlockadeHarriet Kluger, MD

Poster Sessions: S Hall ASaturday, May 30; 8:00 AM - 11:30 AMProspective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.Tara Sanft, MD

A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.Maysa Abu-Khalaf, MD

A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (? 25).Maysa Abu-Khalaf, MD

Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in triple negative breast cancer.Mehmet Altan, MD

Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.Sarah Schellhorn Mougalian, MD

Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.Kurt Alex Schalper, MD/PhD

Poster Sessions: S Hall A

Saturday, May 30; 1:15 PM - 4:45 PMDistress in cancer survivors attending a multidisciplinary survivorship clinic.Tara Sanft, MD

Trends and regional variation of end-of-life cancer care in the Medicare program.Shi-Yi Wang, MD, PhD

Contemporary national trends of prostate cancer screening among privately insured patients in the United States.Simon P. Kim, MD, MPH

Poster Sessions: S Hall A2

Monday, June 1; 8:00 AM - 11:30 AMFirst-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.Scott Gettinger, MD

Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastasesSarah Goldberg, MD

"The burden upon me": The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment.Carolyn Jean Presley, MD

Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small-cell-lung cancer.Elyn H. Wang, BS

Clinical diagnostic utility of a blood-based multi-transcriptome assay for gastroenteropancreatic disease.Irvin Mark Modlin, MD, PhD

Poster Sessions: S Hall A

Monday, June 1; 1:15 PM - 4:45 PMA framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER).Anton Safonov, BS

Education Sessions:

Saturday, May 30; 1:15 PM - 1:35 PMLocation: E Hall D1Recent Positive Clinical Trials and Data in Context of Study Results, Design, and EndpointsRogerio Lilenbaum, MD

Tuesday, June 2; 11:45 AM - 12:00 PMLocation: E450Lung CancerRogerio Lilenbaum, MD

Provided by Yale University

Citation: Yale Cancer Center at 2015 ASCO Annual Conference (2015, May 19) retrieved 25 April 2024 from https://sciencex.com/wire-news/193503378/yale-cancer-center-at-2015-asco-annual-conference.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.